You seem to be using an older version of Internet Explorer. This site requires Internet Explorer 8 or higher. Update your browser here today to fully enjoy all the marvels of this site.
Prof. Richard Bond and Dr Mitchell Glass provide an update on the development of Invion Limited's (ASX:IVX) chronic inflammation treatment.
Invion is a clinical-stage drug development company focussed on the development of treatments for major market opportunities in inflammatory diseases including asthma, chronic bronchitis and lupus.
Show Less 